{"id":4131,"date":"2021-08-02T23:02:44","date_gmt":"2021-08-02T23:02:44","guid":{"rendered":"http:\/\/inevitablecompany.es\/?p=4131"},"modified":"2021-08-27T22:01:06","modified_gmt":"2021-08-27T22:01:06","slug":"an-evidence-based-clinical-consensus-for-latin-america","status":"publish","type":"post","link":"https:\/\/factor-h.org\/pt\/an-evidence-based-clinical-consensus-for-latin-america","title":{"rendered":"Um consenso cl\u00ednico baseado em evid\u00eancias para a Am\u00e9rica Latina"},"content":{"rendered":"<p><strong>Objetivos das Diretrizes de Pr\u00e1tica Cl\u00ednica para o Manejo da Doen\u00e7a de Huntington na Am\u00e9rica Latina<\/strong><\/p>\n<p>Eu<strong>m 2020, o Factor-h obteve uma bolsa da Roche para um projeto de gera\u00e7\u00e3o de um consenso cl\u00ednico baseado em evid\u00eancias para os pa\u00edses da Am\u00e9rica Latina. O objetivo geral deste consenso \u00e9 abordar os problemas de sa\u00fade e melhorar o padr\u00e3o de vida dos pacientes sintom\u00e1ticos e assintom\u00e1ticos da doen\u00e7a de Huntington e suas fam\u00edlias na Am\u00e9rica Latina. O programa teve in\u00edcio em dezembro de 2020 e tem dura\u00e7\u00e3o de 12 a 16 meses.&nbsp;<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"171\" src=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-300x171.png\" alt=\"\" srcset=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-300x171.png 300w, http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-1024x583.png 1024w, http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-768x437.png 768w, http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-1536x875.png 1536w, http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/05\/Roche_logo_logotype-2048x1166.png 2048w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\"><\/p>\n<p><strong>Objetivos espec\u00edficos<\/strong><\/p>\n<p><strong>1.1.&nbsp;<\/strong>Otimizar o diagn\u00f3stico cl\u00ednico e molecular e o aconselhamento gen\u00e9tico para indiv\u00edduos afetados pela doen\u00e7a de Huntington (HD) e suas fam\u00edlias na regi\u00e3o.<\/p>\n<p><strong>1.2.&nbsp;<\/strong>Promover o monitoramento e implementa\u00e7\u00e3o das diretrizes internacionais para diagn\u00f3stico, aconselhamento gen\u00e9tico, preven\u00e7\u00e3o, sa\u00fade, tratamento e reabilita\u00e7\u00e3o validadas em n\u00edvel global, em pacientes da regi\u00e3o.<\/p>\n<ul>\n<li>Facilitar a forma\u00e7\u00e3o de profissionais da \u00e1rea da sa\u00fade e \u00e1reas afins.<\/li>\n<li>Promover o desenvolvimento de projetos de pesquisa cl\u00ednica, b\u00e1sica e translacional para esta patologia.<\/li>\n<li>Esfor\u00e7ar-se para a aplica\u00e7\u00e3o integral do conhecimento derivado desta pesquisa, tanto em estrat\u00e9gias de preven\u00e7\u00e3o como no diagn\u00f3stico e tratamento da popula\u00e7\u00e3o afetada.<\/li>\n<li>Gerar equipes de trabalho multidisciplinares para garantir tratamento adequado, reabilita\u00e7\u00e3o e aconselhamento gen\u00e9tico para os pacientes afetados e suas fam\u00edlias.<\/li>\n<\/ul>\n<p><strong>Metodologia para o desenvolvimento das Diretrizes de Pr\u00e1tica Cl\u00ednica para o Manejo da Doen\u00e7a de Huntington na Am\u00e9rica Latina<\/strong><\/p>\n<p>Considerando que o principal motivo desse consenso \u00e9 fazer recomenda\u00e7\u00f5es sobre diagn\u00f3stico, preven\u00e7\u00e3o, conduta terap\u00eautica e reabilita\u00e7\u00e3o para a doen\u00e7a de Huntington, \u00e9 relevante para o Fator H que tais recomenda\u00e7\u00f5es sejam apoiadas por evid\u00eancias cient\u00edficas.<\/p>\n<p>Nesse sentido, para a se\u00e7\u00e3o Diretrizes a metodologia escolhida \u00e9 a <strong>NOTA<\/strong> metodologia \u2013 o Sistema de avalia\u00e7\u00e3o, desenvolvimento e avalia\u00e7\u00e3o de classifica\u00e7\u00e3o de recomenda\u00e7\u00f5es para classifica\u00e7\u00e3o de evid\u00eancias.<\/p>\n<p>A abordagem Grading of Recommendations Assessment, Development and Evaluation (GRADE) fornece um sistema para classificar a qualidade das evid\u00eancias e a for\u00e7a das recomenda\u00e7\u00f5es que \u00e9 expl\u00edcito, abrangente, transparente e pragm\u00e1tico, e est\u00e1 sendo cada vez mais adotado por organiza\u00e7\u00f5es em todo o mundo<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"592\" height=\"352\" src=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/08\/GRADE.jpg\" alt=\"\" srcset=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/08\/GRADE.jpg 592w, http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/08\/GRADE-300x178.jpg 300w\" sizes=\"auto, (max-width: 592px) 100vw, 592px\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Objectives of the Clinical Practice Guidelines for the Management of Huntington\u2019s Disease in Latin America In 2020, Factor-h obtained a grant from Roche for a project to generate an evidence-based clinical consensus for Latin America countries.&nbsp;The general objective of this consensus is to approach the health problems and improve the standard of living of symptomatic [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4143,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[82,64,53,9,51,42],"tags":[],"class_list":["post-4131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-consensus","category-advocacy","category-health-disease-management","category-general-news","category-ongoing","category-we"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts\/4131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/comments?post=4131"}],"version-history":[{"count":0,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts\/4131\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/media\/4143"}],"wp:attachment":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/media?parent=4131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/categories?post=4131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/tags?post=4131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}